Trial Profile
An Open-Label Study of Rovalpituzumab Tesirine in Subjects With Delta-Like Protein 3-Expressing Advanced Solid Tumors
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Oct 2021
Price :
$35
*
At a glance
- Drugs Rovalpituzumab tesirine (Primary)
- Indications Gastrointestinal cancer; Glioblastoma; Large cell carcinoma; Malignant melanoma; Neuroendocrine carcinoma; Pancreatic cancer; Prostate cancer; Solid tumours; Thyroid cancer
- Focus Adverse reactions
- Sponsors AbbVie; Stem CentRx
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 29 Aug 2019 Status changed from active, no longer recruiting to discontinued.According to an AbbVie media release, the company discontinues Rovalpituzumab Tesirine (Rova-T) Research and Development Program
- 21 May 2019 Planned End Date changed from 1 Sep 2020 to 27 Aug 2019.